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Abstract 
BACKGROUND: Smokers are exposed to significant doses of carcinogens, including tobacco-
specific nitrosamines (TSNAs). Previous studies have shown significant global differences in the 
levels of TSNAs in cigarette smoke because of the variation in tobacco blending and curing 
practices around the world.  
METHODS: Mouth-level exposure to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) 
measured in cigarette butts and urinary concentrations of its major metabolite 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) were examined among 126 daily smokers 
in four countries over a 24-hour study period.  
RESULTS: As mouth-level exposure of NNK increased, the urinary NNAL increased, even after 
adjustment for other covariates (β=0.46, p=0.004). The relationship between mouth-level 
exposure to nicotine and its salivary metabolite, cotinine, was not statistically significant (β=0.29, 
p=0.057), likely because of the very limited range of differences in mouth-level nicotine 
exposure in this population.  
CONCLUSIONS: We have demonstrated a direct association between the 24-hour mouth level 
exposure of NNK resulting from cigarette smoking and the concentration of its primary 
metabolite, NNAL, in the urine of smokers.  Internal dose concentrations of urinary NNAL are 
significantly lower in smokers in countries which have lower TSNA levels in cigarettes such as 
Canada and Australia in contrast to countries which have high levels of these carcinogens in 
cigarettes, such as the United States. Lowering the levels of NNK in the mainstream smoke of 
cigarettes through the use of specific tobacco types and known curing practices can significantly 
impact the exposure of smokers to this known carcinogen.  
Introduction 
 
Tobacco smoke is a complex aerosol mixture containing many toxic and carcinogenic 
compounds (1). Of particular concern are the tobacco-specific nitrosamines (TSNAs), which 
include 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), N-nitrosonornicotine (NNN), 
N-nitrosoanabasine (NAB), and N-nitrosoanatabine (NAT). These compounds form via 
nitrosation of tobacco alkaloids (nicotine, nornicotine, anabasine, anatabine) during the curing 
process. Several factors contribute to TSNA formation, including use of nitrate fertilizers, NOx 
gas availability, microbial activity, curing temperature, humidity during curing and storage, and 
tobacco variety (1–5).  
Given the variability of TSNA levels among commercially available brands both within 
and among countries (6–9), cigarette manufacturers can produce cigarettes with fewer TSNAs. 
Although the actual degree of health benefit from lowering TSNAs in cigarettes is uncertain, the 
World Health Organization Study Group on Tobacco Product Regulation (TobReg; 10) has 
recommended that TSNA levels be lowered. This recommendation is based on the fact that NNN 
and NNK are International Agency for Research on Cancer Group 1 known human carcinogens 
and suspected to significantly contribute to the cancer burden of smokers. 
TSNAs are implicated in the development of human lung adenocarcinoma and have been 
shown in experimental studies to produce adenocarcinomas in laboratory animals (11–13). DNA 
adducts formed by NNN and NNK are likely to be important in carcinogenesis in smokers, as 
adducts left unrepaired can eventually lead to mutations (11). NNK is metabolized to NNAL, and 
total (or free) NNAL and its glucuronides are established biomarkers for NNK exposure 
measurable in human urine (14–19). Total NNAL has been shown to correlate with urinary 
cotinine, although the ratio of NNAL to cotinine may decrease as cotinine levels increase (20, 
21).  
Only a few studies to date have compared exposure levels of TSNAs between persons 
smoking brands of cigarettes known to differ significantly in TSNA smoke levels. These studies 
have focused on potentially reduced exposure products (PREPs) (22–24). For example, Breland 
and colleagues (22) measured total NNAL levels in smokers who were switched to Advance, a 
brand marketed as having 80% lower nitrosamine yields based on levels determined by the 
International Organization for Standardization (ISO) machine smoking regimen. The researchers 
found that NNAL levels were reduced 51% compared with the levels found when the smokers 
used their usual brands—a significant reduction in NNAL, although less of a reduction than 
when the same individuals abstained from smoking for a week.  
In another study, Hughes et al. (23) examined smoking behavior, urine cotinine, and 
NNAL levels in smokers who switched from their usual brand to Omni cigarettes, another 
purportedly low nitrosamine brand. The researchers found that, in spite of the reported lower 
NNK smoke emissions from Omni cigarettes, NNAL concentrations were not significantly lower 
in the urine of smokers who switched to Omni for 6 weeks. However, smokers may have 
substituted their regular brand during the switching study, which would have confounded the 
results.  
Finally, Hatsukami et al. (24) examined smokers’ urinary concentrations of cotinine and 
NNAL after smokers switched to Omni cigarettes or medicinal nicotine. They found that, for 
those cigarette smokers who switched to Omni cigarettes, NNAL concentrations in the urine 
were reduced significantly (32%). 
These switching studies are informative in determining if smokers who switch to lower 
TSNA cigarettes will experience lower levels of these carcinogens. However, they are limited by 
recruitment of subjects who may not be interested in these products and, consequently, may not 
smoke as much as individuals who self-select to use these products. In addition, subjects in these 
studies may not fully comply with using only the product assigned to them. When switching to a 
new product, smokers often adapt their smoking behavior to compensate for differences in 
nicotine delivery and the sensory properties of a cigarette (25). For example, smokers may 
change the number of cigarettes smoked per day and/or vary the amount of smoke inhaled from 
each cigarette (26). In these forced-switching studies, such changes can influence biomarker 
results.  
However, the wide variability in TSNA levels across tobacco markets provides an 
opportunity to conduct natural experiments on the association between TSNA levels from 
cigarettes and biomarker concentrations of TSNAs among people who smoke their accustomed 
cigarette brands. No study to date has actually compared biomarker levels of TSNAs in persons 
smoking their usual brand of cigarettes, including smokers of brands that vary substantially in 
nitrosamine levels. 
The number of cigarettes smoked per day has long served as a standard exposure measure 
for epidemiologic research on smoking and health (27), but it provides only a crude estimate of 
human exposure, particularly when assessing differences among tobacco products. Biomarkers 
are a possible alternative measure of total smoke exposure but provide an aggregate measure of 
exposure over hours, days, or even weeks, depending on the specific compound’s clearance rate. 
Biomarkers can also be influenced by individual differences in metabolism, complicating the 
interpretation of results. This limitation has revived interest in complementary mouth-level 
indicators of smoke exposure. Mouth-level indicators include measures of smoking topography 
by using flow-meter-type devices (e.g., 26, 28), cigarette filter staining patterns (29–31), or 
chemical assays of the filter (32, 33). A method of estimating smoke exposure by using solanesol, 
a naturally occurring component in tobacco deposited during smoking in the cigarette filter butt, 
has also been developed (34, 35). Solanesol levels can be used to model emissions of other 
constituents, such as nicotine and TSNAs. 
In the current study, we sought to evaluate the extent to which the mouth-level exposure 
to NNK and nicotine assessed from filter butts related to the urinary levels of NNAL and salivary 
cotinine in smokers who smoked cigarette brands with different levels of TSNAs. The study was 
conducted in four countries: the United States, where American-blend cigarettes containing 
burley tobacco have high levels of TSNAs, and Canada, the United Kingdom, and Australia, 
where cigarettes typically made only from bright tobacco have substantially lower TSNA levels 
than cigarettes in the United States (6, 7).  
 
Materials and Methods 
Subjects 
The subjects were 126 adult daily smokers recruited in four countries: Australia, Canada, 
the United Kingdom, and the United States. Subjects were recruited through advertisements in 
local newspapers, flyers, emails, or posters on public bulletin boards at five different sites: 
Waterloo, Canada; Melbourne, Australia; London, United Kingdom; and Buffalo and 
Minneapolis, United States. Smokers who responded to the advertisements were screened for 
eligibility by a brief telephone interview. Subjects were included if they were between 18 and 55 
years of age, had smoked at least 10 cigarettes daily for the past year, and had been a regular 
smoker of one particular cigarette brand for more than 3 months. Seventeen eligible cigarette 
brands (between three and five brands from each country) were selected on the basis of national 
sales and nicotine yield to identify popular brands with a range of ISO nicotine yields. Smokers 
were excluded if they smoked an ineligible cigarette brand, had a history of lung or heart disease, 
or were pregnant. See Table 1 for a summary of the sample profile. The study was approved by 
the Institutional Review Boards at the U.S. Centers for Disease Control and Prevention (CDC); 
Roswell Park Cancer Institute; the University of Waterloo, Canada; the University of Minnesota; 
the University at Buffalo, State University of New York; University College London; and the 
Cancer Council Victoria, Australia. 
 
Data collection protocol 
Data collection occurred during April–November 2005 at each of the five study sites. 
Subjects completed a brief telephone interview to ascertain eligibility and were booked for two 
1-hr laboratory visits on consecutive days. The study procedure has been described elsewhere 
(36).  
Briefly, subjects visited the laboratory on two occasions, 24 hrs apart, and were instructed 
to abstain from smoking for at least ½ hr before each visit. At the subjects’ first visit, researchers 
explained the purpose of the study; obtained written consent; and recorded basic smoking, socio-
demographic, and anthropometric characteristics (i.e., height and weight). At both visits, subjects 
provided additional details about recent (within 24 hrs) smoking behavior before saliva and urine 
samples were collected. At the end of each visit, subjects smoked a cigarette through a smoking 
topography device (data not included), and the spent cigarette butt was collected. Between visits, 
subjects were asked to continue smoking as usual and were provided with a container to collect 
all the butts from the cigarettes they smoked in the intervening 24-hr period. Subjects were 
reimbursed the equivalent of $50 USD for their time.  
The urine, saliva, and used cigarette butts collected from participants were frozen after 
each visit. Upon conclusion of the study, all biospecimens and cigarette butt samples were placed 
on dry ice and shipped to CDC for analysis. 
 
Data cleanup 
 Data describing each subject, including demographics, smoking history, cigarette butt 
collection dates and times, and any deviations from the protocol, were compiled in identical 
spreadsheets at each site for further processing. Consistency of replies between the two 
questionnaire sessions was examined to assess the data for obvious outliers and compare 
reported information for internal consistency. The field sites were contacted for clarification of 
data questions, and identifiable errors were corrected. Subjects were excluded from data analysis 
if they failed to follow the study protocol by 
 smoking other brands of cigarettes, 
 failing to attend the appointments, 
 using other nicotine products, 
 failing to collect more than 75% of the butts from cigarettes smoked during the period, 
 failing to record dates and times of smoking, 
 smoking immediately before the visit, and 
 returning butts which by observing the filter showed no sign of having been from a 
smoked cigarette 
Of 157 subjects who enrolled in the study, 126 (80%) fully complied with the study protocol and 
were included in this analysis. 
 
Machine smoking conditions for determining cigarette emissions  
Cigarettes were conditioned at 22C and 60% relative humidity before testing. An 
ASM500 16-port linear smoking machine (Cerulean, Milton Keynes, UK) was used for machine 
smoking. Systematic variation of puff volume, puff frequency, and filter ventilation blocking 
provided a wide range of smoking conditions and resultant mainstream smoke deliveries (35). 
After the cigarettes were smoked, the filters were detached from the residual tobacco column and 
stored in cryovials (Nalgene, Rochester, NY) at -20ºC until further processing. 
  
Nicotine and TSNA determination 
 The TSNAs captured during machine smoking on a Cambridge filter pad (CFP) were 
quantified by using an Agilent 1100 liquid chromatograph (LC, Wilmington, DE) and API 4000 
tandem mass spectrometer (MS/MS, Sciex, Toronto, ON) as previously published (37). Sample 
preparation was streamlined with direct extraction of the CFPs in the LC mobile phase (38), 20 
mM ammonium acetate containing 5% methanol. One hr before the cigarettes were smoked, the 
CFPs were treated with 2 mL of 50 mM ascorbic acid in methanol to reduce TSNA artifact 
formation (37, 39). 
Mainstream smoke nicotine levels were determined by using a combined LC-MS/MS 
approach that incorporated nicotine in our standard TSNA method. Isotopically labeled nicotine 
was included in the TSNA internal standard panel for nicotine quantification. This method 
allowed the quantification of both nicotine and TSNAs on CFPs that collected mainstream 
smoke, along with the analysis of solanesol on the cigarette filter from which this smoke was 
drawn. We compared nicotine results obtained by using LC-MS/MS and standard gas 
chromatography flame ionization detection method (40) and confirmed equivalency of the results. 
 
Solanesol analysis 
Portions of the cigarette filters (1-cm length) removed from the mouth end were stripped 
of the wrapping paper and loaded into glass vials. The 1-cm portions were analyzed as 
previously described (35). Briefly, cigarette filter butts were spiked with geranylgeraniol, placed 
in 1N methanolic potassium hydroxide, and extracted with hexane. The butts were then analyzed 
by using normal phase liquid chromatography and single quadruple atmospheric pressure 
chemical ionization mass spectrometry in selected ion monitoring mode. 
 
Calculation of mouth-level exposure to TSNAs and nicotine 
Results from analyzing solanesol in cigarette butts were used to calculate mouth-level 
exposure of NNN, NNK, and nicotine by using relationships established by smoking cigarettes 
from each brand under a wide range of conditions, as described above (35). Regression analysis 
was done to determine solanesol levels in butts and to determine nicotine, NNN, or NNK 
collected on CFPs analyzed in samples resulting from smoking the same cigarettes, but under 
multiple smoking conditions. This analysis allowed butt levels of solanesol to be used to 
calculate target compound levels emitted from the mouth-end of the smokers’ discarded cigarette 
butts.  
Where the relationship between solanesol and the delivered component deviated from 
linearity at low delivery levels, a separate correlation was determined over this range and mouth-
level exposure for these study butts was recalculated. Of the butts tested, 1.6% of the NNN, 2.0% 
of the NNK, and 3.3% of the nicotine results were recalculated in this manner.  
Some solanesol levels that were determined on submitted butts were greater than the 
maximum levels achievable by using the most intense machine smoking conditions. The levels 
of TSNAs and nicotine from the smokers’ cigarette butts that had solanesol levels above the 
highest machine-determined levels were calculated by extrapolating the solanesol-delivered 
component comparison curves. Of the butts tested, 1.9% of the results were determined by 
extrapolation.  
For butts that were not collected by the subjects or for which analysis results were not 
reportable, a mean of all of the submitted butts for each subject was calculated and substituted 
for these undetermined results. Of the butts tested, 4.1% of the results were replaced by mean 
levels that were determined individually for each subject. This step was required so that the total 
mouth-level exposure of smoke constituents over the 24-hr period would not be biased for 
subjects for whom all results were not available. 
 Mouth-level exposures of the individual TSNAs—NNN and NNK—and nicotine were 
determined for each cigarette butt submitted and summed to create 24-hr NNN, NNK, and 
nicotine mouth-level exposures for each subject. In the case of the cigarette butts submitted from 
Minneapolis, butts collected from the two cigarettes the subjects smoked during clinic visits were 
not obtained and submitted for analysis. Therefore, the 24-hr mouth-level exposure of 
constituents for subjects from Minneapolis was calculated as the submitted butts plus two times 
the average. 
 
Salivary cotinine 
Saliva samples were collected by having subjects gently chew on the sterile cotton swabs 
from a Salivette (Sarstedt, Newton, NC) for approximately 2 min, after which the swab was 
returned to the device. The intact Salivettes were stored frozen at <-20
o
C and shipped to the 
laboratories at CDC, where they were kept frozen until analysis. Samples were, subsequently, 
extracted into methylene chloride, reconstituted in water, and analyzed by LC-MS/MS by using a 
method described previously (41, 42). The cotinine concentration was quantified by comparing 
unknown relative response factors of unknowns to standards using least-squares linear regression. 
 
Urinary NNAL 
Urinary NNAL was measured as free (i.e., nonconjugated) NNAL and also as total 
NNAL after hydrolysis of NNAL-glucuronide. All samples were analyzed by slightly modifying 
a previously described method using LC-MS/MS (14). Total NNAL was measured following an 
overnight incubation with ß-glucuronidase. Following the incubation, the hydrolyzed solution 
was made basic by adding 100 μL of 10 N NaOH and loaded onto a prewashed ChemElute 
column that was eluted twice with 4 mL of methylene chloride. The pooled methylene chloride 
extracts were then back-extracted into 3 mL of 0.1 N HCl. The aqueous HCl extract was 
neutralized with NaOH, and 3 mL of phosphate buffer pH 6.4 was added. This sample was then 
processed through a custom molecularly imprinted polymer (MIP) column (MIP Technologies). 
Free NNAL samples were prepared in the same manner, except the initial hydrolysis was omitted 
and the samples were processed directly through the ChemElute and MIP columns as described 
above. Analysis and quantification of NNAL were also as described previously (14), except that 
we used an API 5000 mass spectrometer and an Xterra RP18 column (5 μm, 3.0 x 150 mm) from 
Waters (Milford, MA). 
Urinary creatinine 
Urinary creatinine was assayed by the Roche CREA plus procedure using a Hitachi 
analyzer. This enzymatic procedure is optimized to provide minimum interferences from 
ascorbate and ketone bodies, and it generates results that correlate well with specific high-
performance liquid chromatography methods. 
 
Statistical analysis 
 Data were analyzed by using SAS (SAS Institute, Cary, NC) and SUDAAN (Research 
Triangle Institute, RTI, NC). Proc MEANS and TTEST were used to compute descriptive 
statistics and to test for statistical differences between pairs of variables. SUDAAN Proc 
REGRESS was used to fit regression models for mouth-level exposures and biomarkers. Because 
these variables are log-normally distributed, they were log-transformed before modeling and 
related analyses. Geometric means and their 95% confidence intervals adjusted for other 
variables in the model were computed for each site and gender. Because of the short half-life of 
salivary cotinine (18-24 hr), levels for the visits were averaged to obtain more consistent 
measures for each subject over the study period. Levels of total and free NNAL from only the 
second visit were used for comparison to mouth-level exposure of NNK because the NNAL 
biomarker has a half-life of approximately 40–45 days, and levels are not expected to change 
appreciably between visits (43). All reported statistical differences were based on a p-value less 
than 0.05. 
 
Results  
Table 1 provides summary information on subjects from each site and the filter 
ventilation of the cigarettes smoked. The ages of the subjects included in the study ranged from 
18–52 years. The mean self-reported number of usual cigarettes smoked per day was lowest for 
subjects from the United Kingdom and was significantly different (p <0.05) from the means 
reported by subjects from Australia and Minnesota. The actual number of cigarettes smoked 
during the 24-hr study period was significantly higher (p <0.05) for subjects from Australia 
compared with subjects in New York and the United Kingdom. Across sites, the self-reported 
average cigarettes-per-day values were higher than the actual number of cigarettes smoked over 
the 24-hr period of the study, with mean discrepancies ranging from 1.0 to 3.0 cigarettes per day. 
 Cigarette brands from each study location reflect differences in product regulation and 
preferences of the subjects included in the study (Table 1). In the United Kingdom, all of the 
cigarette brands from the subjects tested had ventilation greater than 20%. This ventilation is 
likely due to the European Union “10-1-10” regulation, limiting emissions to 10 mg each of tar 
and carbon monoxide and 1.0 mg of nicotine under machine testing by using the ISO regimen. 
Cigarettes from Australia also tended toward higher ventilation, with approximately half of the 
subjects smoking cigarette brands having ventilation of 5%–20% and half of the subjects 
smoking cigarette brands with ventilation of >20%. Cigarette brands smoked by the subjects 
from Canada were highly weighted toward lower ventilation, with 84% having ventilation <5%. 
 
Mouth-level exposure to nicotine and nitrosamines 
Table 2 provides summary data on the mouth-level exposure of nicotine, NNN, and NNK 
during the 24-hr test period. The subjects from the five sites clustered in two groups based on the 
24-hr mouth-level exposure to nicotine: Levels of nicotine in subjects in Australia and Canada 
were similar but were significantly higher than levels in subjects in New York, Minnesota, and 
the United Kingdom, which were not statistically different from each other based on significance 
testing. The 24-hr mouth-level exposure to nicotine for subjects from the United Kingdom, 
where all cigarettes had ventilation of >20%, was not statistically different than the mouth-level 
exposure of subjects from Minnesota and New York, where many cigarettes have lower 
ventilation (Tables 1 and 2). 
 Also shown in Table 2 are the large differences in NNN and NNK levels among sites. 
The 24-hr NNN mouth-level exposure of subjects from Canada was the lowest, with smoke 
NNN mouth-level exposure of smokers in Australia only slightly, but statistically significantly, 
higher. Levels of 24-hr mouth-level NNN exposure of subjects from the United Kingdom were at 
an intermediate level and not significantly different from the other groups. The 24-hr NNN 
mouth-level exposure of subjects in both U.S. locations (New York and Minnesota) was much 
higher than levels in the other countries. The wide range of these mouth-level exposures is 
clearly evident because the geometric mean of the 24-hr mouth-level NNN exposure of subjects 
in New York was more than 12 times higher than in Canada. In all cases, the differences in the 
log of 24-hr mouth-level NNN exposure for subjects among all sites were statistically significant 
(p <0.05). Similarly, the 24-hr mouth-level NNK exposures were highest in New York and 
lowest in Australia. All of the mouth-level NNK exposures between sites were statistically 
different (p <0.05), except the 24-hr mouth-level NNK exposures of subjects in Canada vs. 
Australia, New York vs. Minnesota, and Minnesota vs. the United Kingdom. Thus, we were able 
to obtain samples from subjects with a wide range of TSNA mouth-level exposure. 
 
Relationship of urinary NNAL to mouth-level exposure 
We fitted a multiple regression model to examine the relationship between 24-hr mouth-
level NNK and urinary total NNAL (both natural log transformed) after adjusting for the unique 
contributions of covariates. These covariates included urinary creatinine, minutes since the last 
cigarette, cigarette ventilation, body mass index, age, study site, and gender. In this analysis, 24-
hr mouth-level NNK exposure (β=0.46, p=0.004) was positively correlated with the log of 
urinary NNAL. Gender (β=0.13, p=0.03), age (β=0.006, p=0.04), and creatinine (β=0.003, p 
<0.0001) were also positively correlated with the log of urinary NNAL. Minutes since the last 
cigarette (β=-0.002, p=0.008) and cigarette ventilation (β=-0.006, p=0.02) were inversely 
associated with the log of urinary NNAL. Body mass index was not a statistically significant 
determinant of urinary NNAL. In addition, controlling for other predictors in the model, the log 
urinary NNAL in subjects from Canada was significantly different from subjects from the United 
Kingdom (p=0.02) and New York (p=0.003). The log urinary NNAL in subjects from New York 
was significantly different from subjects from Minnesota (p=0.03). The multivariate model 
accounted for 63% of the total variance in log urinary NNAL. 
 
Relationship of salivary cotinine to mouth-level exposure 
We conducted a regression analysis to examine the relationship between 24-hour mouth-
level nicotine with salivary cotinine (both log transformed), controlling for the same covariates, 
except creatinine, as the above analysis. Surprisingly, we found that 24-hr mouth-level nicotine 
was not a robust predictor of salivary cotinine (β=0.29, p=0.057) once other factors were 
included in the model. Minutes since the last cigarette (β=-0.001, p=0.02) and cigarette 
ventilation (β=-0.006, p=0.003) were inversely correlated with log of salivary cotinine, while age 
(β=0.003, p=0.01) was positively correlated with the log of salivary cotinine. Body mass index 
was not significantly associated with salivary cotinine. We observed, controlling for the above 
factors, that cotinine levels in Australian subjects were significantly different from those in 
Canadian (p=0.02) and New York (p=0.006) subjects. However, the multivariate model 
accounted for only 30% of the total variance in salivary cotinine. 
 
Discussion 
This study clearly documents that smokers have lower NNAL levels in their urine when 
they have lower mouth-level exposure to TSNAs in mainstream smoke from their usual cigarette 
brands. Mouth-level exposure as assessed by using spent cigarette filters is a valid predictor of 
downstream levels of NNAL in urine. The study design was made possible by the substantial 
differences in mainstream smoke TSNA levels across countries differing substantially in tobacco 
blend and curing practices (6, 9, 44–48). Our finding is in agreement with previous switching 
studies that examined biomarker levels in smokers alternatively using their usual cigarette brands 
and cigarettes with lower TSNA levels (22–24). However, this study is the first to examine 
differences in TSNA exposure among smokers from different countries, in which leading 
cigarette brands have very greatly differing TSNA levels. This study is also the first to examine 
TSNA exposure by using both mouth-level exposure and urine biomarkers. 
Table 3 shows the crude geometric means of biomarkers of exposure separated by study 
site without adjustment for covariates (other than creatinine concentration in the urinary NNAL 
results). The levels of salivary cotinine showed very limited variation among sites, as expected, 
because, on average, smokers adjust the way they smoke to obtain a similar dose of nicotine. In 
contrast, creatinine-corrected total NNAL levels ordered from highest to lowest thusly: New 
York, Minnesota, the United Kingdom, Australia, and Canada. Figure 1 shows the relation 
between the geometric means of the 24-hr smoke intake of NNK versus the geometric means of 
the creatinine-normalized total urine NNAL levels for the five different sites, along with 95% 
confidence intervals. An overall relationship is evident: The subjects from sites with higher 
levels of mouth-level exposure of NNK in smoke have higher levels of NNAL in their urine.  
As expected, both urinary NNAL and mouth-level exposure to NNK were much higher 
among smokers from the United States, where American-blend cigarettes have higher levels of 
TSNAs, and lower among smokers in Canada (49, 50) and Australia, where only bright tobacco 
with lower levels of TSNAs predominates. Levels in the United Kingdom fell in the middle of 
the range of exposures. Mouth-level exposure to NNN and NNK between subjects from 
Minnesota and New York were moderately different, likely resulting from dissimilarity in the 
subject populations between these two sites. The study was not designed to sample equivalent 
populations at the sites but to provide a wide range of mouth-level exposure to TSNAs.  
Finding wide variation in mouth-level exposure to TSNAs reflected in biomarkers of 
exposure reveals that exposure to a class of potent carcinogens (i.e., TSNAs) found at high levels 
in cigarettes manufactured in the United States can be easily reduced in smokers by changing the 
curing practices and blend of tobacco used in manufacturing cigarettes. However, the selective 
reduction of particular classes of harmful constituents such as TSNAs does not necessarily 
translate into a measurably less harmful product. For example, even though we found expected 
differences in biomarkers of TSNAs between smokers with different mouth-level exposure, we 
did not measure exposure to the many other toxins in tobacco smoke that could differ among 
cigarette brands and are known to vary by tobacco blend (51). 
The range of mouth-level nicotine exposure under natural free-smoking conditions 
determined by using the butt solanesol method in this study (site geometric means ranged 18.6 to 
27.4 mg/24 hrs) was comparable to previous measures of delivered smoke nicotine. Benowitz 
and Jacob (52) measured nicotine intake by sampling blood and urine in smokers using their own 
brand, a high-delivery brand, and a low-delivery brand. While smoking their own brand, the 
subjects smoked an average of 35 mg nicotine over a 24-hr period. Benowitz and Jacob (53) also 
examined the daily intake of nicotine in 22 smokers of medium- to high-yield cigarettes who 
were smoking their usual brand of cigarette. In that study, the daily intake of nicotine averaged 
37.6 mg (range of 10.5 to 78.6 mg). In both of the studies by Benowitz and Jacob, subjects were 
smokers who smoked at least one pack of cigarettes per day, a rate that may explain the higher 
daily nicotine intake in their studies compared with ours. Although our subjects smoked at least 
10 cigarettes per day, they smoked fewer cigarettes and obtained less daily total nicotine than 
Benowitz and Jacob’s subjects. Forbes et al. (54) examined 24 subjects under normal conditions 
who smoked two brands of cigarettes differing in machine-smoked deliveries. They used the 
amount of nicotine trapped in the filter of each cigarette smoked and filter efficiency to calculate 
mouth-level exposure of each subject. They found that daily mouth-level nicotine exposure 
averaged 19.09 mg/day (range of 3.70–52.90). Thus, our results are in reasonable agreement with 
these previous studies.  
In general, for sites with high mouth-level NNK, the levels of NNAL were higher. Thus, 
if the mouth-level exposure of TSNAs in smoke were decreased and all other factors (nicotine, 
ventilation, etc.) remained the same, a decrease should occur in the amount of TSNAs delivered 
to the smoker as measured in the emissions, in exposure as determined in the mouth-level 
exposure, and in levels of internal dose as measured by using biomarkers. When modeled, the 
levels of urinary NNAL were associated with variables that reflect exposure. Thus, minutes since 
the last cigarette and 24-hr NNK were significantly associated with NNAL. The 24-hr mouth-
level exposure to NNK had a greater impact on explaining the variance in total urinary NNAL 
than any other variable except creatinine concentration. The impact of 24-hr mouth-level 
exposure was more important for urinary NNAL than it was for salivary cotinine. The increased 
dependence on actual delivery for NNK likely resulted because NNK levels varied much more 
over the range of products used than did nicotine. 
Given the number of cigarettes smoked within a 24-hr period, we analyzed approximately 
2,000 cigarette butts for solanesol, necessitating the development of a faster, higher throughput 
method using simpler equipment to conduct these assays (35). Although our measure of 
solanesol in butts reflects the amount of smoke pulled from the cigarette, it does not account for 
other differences in smoking topography. Variations in subjects’ depth of inhalation and length 
of time holding cigarette smoke in their lungs could affect exposure to tobacco TSNAs, nicotine, 
and other smoke constituents.  
A relatively small sample size and measurement of mouth-level exposure and biomarkers 
of exposure over 24 hrs only, dictated largely by practical considerations, limit the generalization 
of the results from this study. Future studies should expand the number of subjects, the length of 
time these subjects are monitored and the number of cigarette specimens assessed from each 
subject and should include a wider range of products. This study was not designed to evaluate 
every possible confounder. Other variables, such as individual metabolic rates, also could be 
significantly associated with the relationship between delivery of smoke emissions and 
biomarkers of exposure and would help in assessing the variance of exposure biomarkers to the 
emissions from cigarette smoke. 
Two recent studies (55, 56) have shown a direct association between measured levels of 
NNAL in smokers and the risk of lung cancer. This literature, combined with the findings in our 
current report, suggests that the higher levels of TSNAs in the smoke of leading U.S. cigarette 
varieties lead to higher mouth-level exposure to NNK and increased NNAL in smokers, which 
may be associated with excess lung cancer burden among U.S. smokers. However, although 
TSNAs have been identified as of significant concern, they are not the only harmful tobacco 
smoke constituents, and the extent of reductions in NNK that is necessary to see reductions in 
harm is unclear. Reducing TSNAs alone could adversely affect public health if it resulted in 
elevating other harmful constituents or if it led to public perceptions of increased product safety. 
Careful evaluation is critical when examining the relative risks of tobacco products, particularly 
when trying to juxtapose risks and health endpoints. Nevertheless, this study has shown that 
smoking currently available cigarettes with lower TSNA emissions results in lower internal dose 
levels of NNAL, a biomarker of exposure to the known carcinogen NNK.  
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Table 1. Descriptive statistics for study subjects by site 
 
Country Valid 
Subjects 
Age 
(mean+SE) 
Self-Reported 
Cigarettes/Day 
(mean+SE) 
Cigarettes 
Smoked in 
Past 24 Hours 
(mean+SE) 
% Vent* 
<5 
% Vent 
5–20 
% Vent 
>20 
Canada 25 29.0+1.9 17.3+1.1 15.7+0.9 84 0 16 
US (NY) 25 30.8+2.1 18.3+0.8 15.3+0.8 24 16 60 
US 
(Minn) 
28 31.2+1.8 19.7+1.3 17.3+1.1 50 21 29 
Australia 25 37.7+3.9 19.6+1.2 18.6+1.4 0 44 56 
UK 23 30.2+1.4 15.6+0.9 14.6+0.9 0 0 100 
* - % Vent indicates the percentage of cigarettes from these subjects with tip ventilation in the 
range indicated.  
 
 
Table 2. Smoke constituents mouth-level exposure per 24 hours by site; geometric means 
with their 95% confidence intervals  
 
Study Site N Smoke Nicotine 
(mg/24 hours) 
Smoke NNN*  
(μg/24 hours) 
Smoke NNK† 
(μg/24 hours) 
Geometric 
mean 
95% 
confidence 
limits 
Geometric 
mean 
95% 
confidence 
limits 
Geometr
ic mean 
95% 
confidence 
limits 
Canada 25 24.4 20.3–29.5 246 204–297 449 372–541 
US (NY) 25 20.4 17.8–23.3 3140 2720–3630 1490 1270–1750 
US (Minn) 28 18.6 15.9–21.8 2510 2108–2989 1150 931–1420 
Australia 25 27.4 23.4–32.0 368 303–448 350 289–424 
UK 23 19.0 15.9–22.7 1390 1070–1800 1010 797–1280 
*NNN: N-nitrosonornicotine 
†NNK: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone  
Table 3. Salivary cotinine and creatinine-adjusted total NNAL* levels by site 
 
Country N Salivary Cotinine (ng/mL) Total NNAL—Visit 2— 
Creatinine Normalized  
(ng/mg creatinine) 
Geometric 
mean 
95% confidence 
limits 
Geometric 
mean 
95% confidence 
limits 
Canada 25 268 208–346 0.072 0.054–0.097 
US (NY) 24 236 200–279 0.290 0.203–0.416 
US (Minn) 27 232 174–309 0.217 0.167–0.283 
Australia 25 337
 
289–392 0.109 0.075–0.158 
UK 23 213 169–268 0.139 0.096–0.202 
*NNAL: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 
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Figure 1. Geometric means of 24-hour mouth-level exposure of 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK) (ng) vs. creatinine-corrected concentrations of urinary 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) (ng/g creatinine) for the five study sites. 
Error bars are 95% confidence limits. 
